Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design

AAPS PharmSci

Volumn 4, Issue 4, 2002, Pages

  Bedu Addo, Frank ^a,c   Moreadith, Randall ^b   Advant, Siddharth J ^a  

^a Diosynth RTP Inc   (United States)

^b ThromboGenics NV   (Belgium)

^c Cardinal Health   (United States)

Author keywords

Formulations; Proteins; Staphylokinase; Statistical design

Indexed keywords

BUFFER; SODIUM CHLORIDE; STAPHYLOKINASE; SY 161; AUR PROTEIN, STAPHYLOCOCCUS AUREUS; METALLOPROTEINASE; RECOMBINANT PROTEIN; SY 161 P5; SY 161-P5;

CHEMICAL INTERACTION; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FACTORIAL ANALYSIS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; PH; PREDICTION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; REVIEW; TIME; ANALYSIS OF VARIANCE; ARTICLE; CHEMISTRY; METABOLISM; STATISTICAL MODEL;

ANALYSIS OF VARIANCE; BUFFERS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; METALLOENDOPEPTIDASES; MODELS, STATISTICAL; RECOMBINANT PROTEINS; SODIUM CHLORIDE;

EID: 85046915185     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps040419     Document Type: Review

References (15)

1. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett.1990;268:235-237.
2. Papahadjopoulos D, Allen T, Gabizon A, Mayhew E, Redemann KC, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA.1991;88:11460-11464.
3. Boccu E, Velo GP, Veronese FM. Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase. Pharmacol Res Commun. 1982;14:113-120.
4. Francis GE, Delgado C, Fisher D. PEG-modified proteins. In: Ahern TJ, Manning MC, eds. Stability of Protein Pharmaceuticals. Part B. New York, NY: Plenum Press; 1992:235-263.
5. Venyaminov S Yu, Yang JT. Determination of protein secondary structure. In: Fasman GD, ed. Circular Dichroism and the Conformational Analysis of Biomolecules. New York, NY: Plenum Press; 1996:69-108.
6. Johnson WC Jr. Protein secondary structure and circular dichroism: a practical guide. Proteins. 1990;7:205-214.
7. Anderson M J, Witcomb PJ. DOE Simplified: Practical Tools for Effective Experimentation. Portland, OR: Productivity Inc; 2000.
8. Box GE, Hunter WG, Hunter JS. Statistics for Experimenters: An Introduction to Design, Data Analysis and Model Building. New York, NY: J. Wiley and Sons; 1978.
9. Timasheff SN. Stabilization of protein structure by solvent additives. In: Ahern TJ, Manning MC, eds. Stability of Protein Pharmaceuticals. Part B. New York, NY: Plenum Press; 1992:265-285.
10. Rouan SK. Biotech-based pharmaceuticals. In: Baker GS, Rhodes CT, eds. Modern Pharmaceutics. New York, NY: Marcel Dekker; 1995:843-873.
11. Syto R, Murgolo NJ, Braswell EH, Mui P, Huang E, Windsor WT. Structural and biological stability of the human Interleukin 10 homodimer. Biochem. 1998;37:16943-16951.
12. Tsai PK, Volkin DB, Dabora JM, et al. Formulation design of acidic fibroblast growth factor. Pharm Res. 1993;10:649-659.
13. Wang W. Instability, stabilization and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185:129-188.
14. Arakawa T, Timasheff SN. Mechanism of protein salting in and salting out by divalent cation salts: balance between hydration and salt binding. Biochem. 1984;23:5912-5923.
15. 2 system. Biochem. 1990;29:1914-1923.